TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic m…

Biotechnology

US, Waltham [HQ]

Summary
IR
Fin. Reports
Financials
Leadership & Strategy
Possible Catalysts

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about TScan Therapeutics, Inc.'s gradings, price targets and earnings estimates. None

Earnings
Grading & Price

Reported

Past Estimate Consensus

Future Estimate Consensus

TScan Therapeutics, Inc. can't present any analysts estimates at the moment detail analysis.